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To investigate the molecular epidemiology of pneumococcal nasopharyngeal carriage in Hanoi, Vietnam, we
studied 84 pneumococcal strains retrieved from children with upper respiratory tract infections. Serotypes 23F
(32%), 19F (21%), 6B (13%), and 14 (10%) were found most often. A significant number of strains were
antibiotic resistant. Fifty-two percent of the strains were (intermediate) resistant to penicillin, 87% were
(intermediate) resistant to co-trimoxazole, 76% were resistant to tetracycline, 73% were resistant to erythro-
mycin, and 39% were (intermediate) resistant to cefotaxime. Seventy-five percent were resistant to three or
more classes of antibiotics. A high degree of genetic heterogeneity among the penicillin resistance genes was
observed. In addition, the tetracycline resistance gene tet(M) and the erythromycin resistance gene erm(B) were
predominantly observed among the isolates. Molecular analysis of the 84 isolates by restriction fragment end
labeling (RFEL) revealed 35 distinct genotypes. Twelve of these genotypes represented a total of eight genetic
clusters with 61 isolates (73%). The two largest clusters contained 24 and 12 isolates, and the isolates in those
clusters were identical to the two internationally spreading multidrug-resistant clones Spain 23F-1 and Taiwan
19F-14, respectively. The remaining RFEL types were Vietnam specific, as they did not match the types in our
reference collection of 193 distinct RFEL types from 16 countries. Furthermore, 57 of the 61 horizontally
spreading isolates (93%) in the eight genetic clusters were covered by the seven-valent conjugate vaccine,
whereas this vaccine covered only 43% of the isolates with unique genotypes. According to the serotype
distribution of the nasopharyngeal pneumococcal isolates, this study suggests a high potential benefit of the
seven-valent pneumococcal conjugate vaccine for children in Hanoi.
Streptococcus pneumoniae is one of the major causes of res-
piratory tract infections and invasive diseases in children all
over the world. At present, worldwide about 1 million children
under 5 years of age annually die of pneumococcal disease
(18).
Pneumococci are often part of the nasopharyngeal flora;
especially due to circumstances of crowding, as observed in
day-care centers, nursing homes, and hospitals, the risk of
being colonized with pneumococci is increased (3, 20, 27, 28).
Usually, colonization is not followed by disease, as local bar-
riers at the mucosal level of the respiratory tract and the
human immune system are often protective. However, the bal-
ance between host and pathogen may be disturbed by highly
pathogenic pneumococcal strains or by diminished host de-
fense through viral infections, malnutrition, or immune defi-
ciency (25).
Another problem is the growing (multi)drug resistance
among pneumococcal isolates. The emergence of penicillin-
and multidrug-resistant pneumococci has been observed in
various countries over the last decade. In some countries and
populations, up to 60% of the pneumococcal isolates are re-
sistant to one or more antibiotics (1, 12, 22). A significant
proportion of pneumococcal resistance is the result of the
worldwide spread of a limited number of multidrug-resistant
clones (6, 15, 35, 39).
Prevention of pneumococcal disease has become a major
topic in the battle against pneumococcal disease. The prevail-
ing 23-valent pneumococcal polysaccharide vaccines have been
shown to be immunogenic in adults but not in the group most
at risk of developing pneumococcal diseases, namely, young
children (5). Recently, several conjugate vaccines have been
developed which have proven to be effective in young children,
especially against invasive diseases (2, 11). Unfortunately,
these vaccines are protective against only a limited number of
pneumococcal serotypes. Conjugate vaccines from up to 11
capsular serotypes have been developed, whereas over 90 se-
rotypes exist. In order to evaluate the theoretical coverage of
the vaccines and the effect of vaccination on future serotype
distribution, we need to monitor in detail and on a large scale
the molecular epidemiology of pneumococcal colonization and
infection before and after the implementation of these vac-
cines.
So far, the coverage of the conjugate vaccine has been in-
vestigated in several parts of the world. For instance, approx-
imately 75% of all pneumococcal central nervous system in-
fections in children in Europe, the United States, and Canada
are covered by the seven-valent conjugate vaccine. For China
and Latin America, the rates are 50 and 48%, respectively (14).
Several molecular epidemiological studies have been per-
formed in Asian countries such as Thailand and Taiwan; how-
ever, in most studies the serotype distribution has not been
investigated (8, 34). In South Korea the seven-valent conjugate
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vaccine covered 65% of the isolates retrieved in the period
from 1991 to 1993 (22). Recently, the Asian Network for Sur-
veillance of Resistant Pathogens has studied nasal carriage of
pneumococci in healthy children in Taiwan, South Korea, Sri
Lanka, and Vietnam. The most common serogroups were 6,
23, 19, 14, and 15. Because no subtypes were determined, the
exact vaccine coverage could not be calculated (23).
In this study, we investigated the molecular epidemiology of
84 pneumococcal carriage isolates of children attending several
outpatient departments in Hanoi, Vietnam, with acute respi-
ratory tract infections. The serotype distribution, vaccine cov-
erage rates, resistance patterns, and genetic properties of these
isolates will be discussed.
MATERIALS AND METHODS
Serotyping. Eighty-four S. pneumoniae strains were isolated from the naso-
pharynges of 410 children with upper respiratory tract infections visiting the
outpatient departments of the Vietnam-Cuba Clinic and the Children’s and Bach
Mai Hospitals in Hanoi from September 1997 to December 1999. Bacteriological
diagnosis was performed according to procedures published in the Manual of
Clinical Microbiology (11a), and pneumococci were serotyped by the capsular
swelling method (Quellung reaction) with capular antisera (Statens Seruminsti-
tut, Copenhagen, Denmark).
Susceptibility testing. The susceptibilities of the Vietnam strains to penicillin,
co-trimoxazole, tetracycline, erythromycin, rifampin, vancomycin, ciprofloxacin,
and cefotaxime were determined by the agar dilution method as described
previously (13). To discriminate between susceptible and nonsusceptible strains,
we used the antibiotic breakpoints according to the NCCLS guidelines (26).
Penicillin-binding protein (PBP) genotyping. The genetic polymorphisms of
penicillin resistance genes pbp1a, pbp2b, and pbp2x of the pneumococcal isolates
were investigated by restriction fragment length polymorphism (RFLP) analysis
of the amplified genes, as described previously (4).
Detection and analysis of erm(B) and mef genes. To detect the presence of
erm(B) in the pneumococcal isolates, we used the protocol described by Sutcliffe
et al. (38). In summary, we amplified the genes by PCR and analyzed the
amplified DNA products by agarose gel electrophoresis. The presence of the mef
gene was also detected by PCR (38). In order to discriminate between mef(A)
and mef(E), PCR-RFLP analysis was performed as described by Del Grosso et
al. (9). The amplicon was restricted with BamHI and DraI. The mef(A) gene
contains a single BamHI site, which is absent in the mef(E) gene. Restriction of
mef(A) and mef(E) with DraI yields two and three fragments, respectively.
Detection of tet(M) and tet(O) genes. In order to discriminate between tet(M)
and tet(O), PCR-RFLP analysis was performed. Primers tetOfw (5-TGTCGG
GTTGTCCATAGAG-3) and tetOrev (5-AAATTTACCAATAGCTGGC-3)
were used to amplify tet(O). The primer sequences were based on the tet(O) gene
(GenBank accession number Y07780; positions 1455 to 1474 and positions 1957
to 1976, respectively). Primers tetM-fw (5-CCATTGGTTTATCTGTATCA-3)
and tetM-rev (5-CAGGTTCACCGGTAGTAACA-3) were used to amplify
tet(M). The primer sequences were based on the tet(M) gene (GenBank acces-
sion number X90939; positions 3428 to 3447 and 3930 to 3949, respectively). The
PCR mixture consisted of 25 l of reaction buffer containing 0.5 U of thermo-
stable DNA polymerase diluted in the buffer supplied by the manufacturer
(Integro, Leuvenheim, The Netherlands), 0.2 mM each deoxynucleoside triphos-
phate, 1.5 mM MgCl2, 10 pmol of each primer, and 10 to 50 ng of pneumococcal
DNA. Amplification cycling in a programmable thermal controller (PTC-100;
MJ Research, Watertown, Mass.) consisted of the following steps: predenatur-
ation for 1 min at 94°C, followed by 30 cycles of 1 min at 94°C, 1 min at 57°C, and
1 min at 72°C. Amplification was finished after 3 min at 72°C. A 1.5% agarose gel
in 0.5 TBE (Tris-borate-EDTA) containing 0.1 g of ethidium bromide per ml
was used to visualize the PCR products.
RFEL analysis. The 84 pneumococcal isolates were subjected to DNA finger-
printing analysis. Genotyping of the pneumococcal strains by restriction frag-
ment end labeling (RFEL) analysis was performed as described by Van Steen-
bergen et al. (40) and adapted by Hermans et al. (16). Briefly, purified
pneumococcal DNA was digested with restriction enzyme EcoRI. The DNA
restriction fragments were end labeled at 72°C with [-32P]dATP by using DNA
polymerase (Goldstar; Eurogentec, Seraing, Belgium). The radiolabeled frag-
ments were denatured and separated electrophoretically on a 6% polyacrylamide
sequencing gel containing 8 M urea. Subsequently, the gel was transferred onto
filter paper, vacuum dried (HBI, Saddlebrook, N.Y.), and exposed for various
lengths of time at room temperature to ECL Hyperfilms (Amersham, Little
Chalfont, United Kingdom).
Computer-assisted analysis of RFEL banding patterns. The RFEL types were
analyzed by using the Windows version of GelCompar software (version 4;
Applied Maths, Kortrijk, Belgium) after the RFEL autoradiograms were imaged
with an Image Master desk top scanner (Pharmacia Biotech, Uppsala, Sweden).
To this end, the DNA fragments in the molecular size range of 160 to 400 bp
were explored. The DNA banding patterns were normalized with the pneumo-
coccus-specific bands present in the RFEL banding patterns of all strains. Com-
parison of the banding patterns was performed by the unweighted pair group
method with arithmetic averages (30) and by using the Jaccard similarity coef-
ficient applied to peaks (37). Computer-assisted analysis was carried out, and the
methods were performed and the algorithms were used according to the instruc-
tions of the manufacturer of GelCompar. A tolerance of 1.2% in band position
was applied during comparison of the DNA patterns. For evaluation of the
genetic relatedness of the isolates, we used the following definitions: (i) strains of
a particular RFEL type are 100% identical by RFEL analysis, (ii) an RFEL
cluster represents a group of strains with RFEL types that differ by only one band
(95% genetic relatedness), and (iii) an RFEL lineage represents a group of
strains with RFEL types that differ by less than four bands (85% genetic
relatedness).
International comparison. The Vietnamese genotypes were compared with
the genotypes of an international collection of pneumococcal strains represent-
ing 193 distinct RFEL types originating from 15 different countries in Europe,
Africa, and Asia and from the United States (M. Sluijter, unpublished observa-
tions, 2002), in which all international pandemic clones described by the pneu-
mococcal epidemiological network are present (http://www.wits.ac.za/pmen/
pmen.htm).
RESULTS
Eighty-four isolates retrieved from the nasopharynges of
children under 5 years of age with acute respiratory tract in-
fections were investigated by serotyping, susceptibility testing,
and RFEL analysis. The most frequently observed serotypes
were 23F (32% of strains), 19F (21%), 6B (13%), and 14
(10%). The rate of coverage of the seven-valent conjugate
vaccine (covering serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F)
was 80%. The additive rate of coverage of the 11-valent con-
jugate vaccine (covering the additional serotypes 1, 3, 5, and
7F) was negligible: only one serotype 3 isolate was found, and
isolates of the other three serotypes were absent. The most
common serotypes not covered by the conjugate vaccine were
23A (2%), 6A (4%), and 15 (4%); one isolate could not be
serotyped.
The rate of resistance to one or more antibiotics was 96%.
The three isolates susceptible to all antibiotics were nonvac-
cine capsular types. The proportions of strains resistant to
penicillin, co-trimoxazole, tetracycline, and erythromycin were
39, 71, 76, and 73%, respectively. None of the strains were
resistant to rifampin, vancomycin, or ciprofloxacin. Intermedi-
ate resistance to penicillin, co-trimoxazole, and cefotaxime was
found in 13, 16, and 39% of the strains, respectively. In total,
78% of the strains were multidrug resistant. These multidrug-
resistant strains were of serotypes 23F (24 strains), 19F (17
strains), 6B (12 strains), 14 (6 strains), 9V and 16 (2 strains
each), and 15, 23A, and untypeable (1 strain each).
Molecular analysis of the 84 isolates revealed 35 different
genotypes. Twelve of these genotypes represented eight ge-
netic clusters with 61 isolates (72%) (Fig. 1). The largest clus-
ter, cluster VIII, consisted of 24 isolates of serotype 23F and
RFEL type 015. The second largest cluster was cluster VI,
which consisted of 12 isolates of serotype 19F and RFEL type
006. The third and fourth largest clusters had 10 and 7 isolates,
respectively, and each cluster had two different genotypes. In
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contrast to all other clusters, cluster III, with 10 isolates, har-
bored isolates with two distinct capsular types, namely, sero-
types 19F and 14. Cluster I, with seven isolates, consisted of
serotype 6B strains only (Fig. 1).
Ninety-three percent of the isolates in six of the eight clus-
ters were covered by the seven-valent conjugate vaccine,
whereas only 43% of the isolates with unique genotypes were
covered by the vaccine (Fig. 2).
We compared all Vietnamese RFEL types with the types in
our international database representing 193 isolates from 16
different countries as well as those of all international pan-
demic clones described by the Pneumococcal Epidemiology
Network (http://www.wits.ac.za/pmen/pmen.htm). Two of the
genotypes, comprising the two largest clusters, clusters VIII
and VI, were identical to international clones Spain 23F-1 and
Taiwan 19F-14, respectively. The remaining 33 RFEL types
were Vietnam specific, as these genotypes were not found in
our present database.
PBP genotyping of the 84 pneumococcal isolates revealed 19
distinct types, and the cluster sizes ranged from 1 to 24 strains.
Despite the observation that 61% of the strains were penicillin
susceptible, only 15 isolates displayed wild-type PBP genotype
2-2-2, 2-2-3, or 2-2-71. Isolates in the major RFEL clusters,
clusters VIII and VI, displayed PBP genotypes 1-1-1 and (26)-
3-30, respectively. The pbp1a gene of the last PBP cluster could
not be amplified from 5 of 12 strains. In addition, genetic
analysis of tetracycline resistance genes tet(M) and tet(O) re-
vealed that the tet(M) gene was exclusively observed in 77 of
the 84 pneumococcal isolates (91%). Interestingly, 13 tet(M)-
containing strains were fully susceptible to tetracycline. Finally,
the erythromycin resistance gene erm(B) was present in 70 of
the 84 pneumococcal isolates (83%). Seven of the erm(B)-
containing strains also harbored the mef(E) gene. In the re-
maining 14 strains, erm(B), mef(A), and mef(E) were absent.
Ten erm(B)-containing isolates and one erm(B)- and mef(E)-
containing isolate were erythromycin susceptible (data not
shown).
DISCUSSION
To determine the serotype distribution and theoretical rate
of coverage of the new pneumococcal conjugate vaccines in
Vietnam, we investigated 84 pneumococcal strains isolated
from children under 5 years of age who visited several outpa-
tient clinics in Hanoi with acute respiratory tract infections
during the period from September 1997 to November 1999.
Serotypes 23F (32%), 19F (21%), 6B (13%), and 14 (10%)
were predominantly observed. The theoretical rate of coverage
of the seven-valent conjugate vaccine was 80%. Since several
studies have demonstrated a cross-reactive effect against sero-
type 6A, we assume a cumulative rate of coverage of the
conjugate vaccine of 83% (7, 32). These data are comparable
to those found in studies conducted in Europe and the United
States, where rates of coverage of 60 to 80% are expected (17,
19, 21, 31, 33, 39).
A high rate of drug resistance was observed among the
pneumococcal isolates. Ninety-six percent of the isolates were
(intermediate) resistant to penicillin, co-trimoxazole, tetracy-
cline, erythromycin, or cefotaxime. Seventy-eight percent of
the isolates were resistant to three or more classes of antibi-
otics. This suggests a major problem with respect to treatment
of pneumococcal infections with these antibiotics.
The epidemiological behavior of the pneumococcal strains
isolated from the Vietnamese children was investigated by
RFEL analysis. Among the 84 strains, 35 different genotypes
were observed, of which 12 genotypes represented eight clus-
ters with 61 strains. This indicates that 73% of the strains were
recently transmitted. Ninety-three percent of the clustered iso-
lates displayed capsular serotypes, which are covered by the
seven-valent conjugate vaccine. The two largest clusters, clus-
ters VI and VIII, containing 12 and 24 isolates, respectively,
were identical to international clones Taiwan 19F-14 and Spain
23F-1, respectively. The remaining clusters, with 42% of the
recently transmitted strains, and all strains with unique geno-
types were considered to be Vietnam specific, as they were not
previously observed for isolates from the 16 countries present
in our database. These data indicate that strains of nationally
and internationally spreading genotypes make a significant
contribution to nasopharyngeal carriage and, consequently, re-
spiratory tract infections among children in Hanoi. The four
largest clusters, with 53 strains, i.e., 87% of the disseminating
isolates, were multidrug resistant. This indicates a significant
transmission of multidrug-resistant pneumococci among chil-
dren in Hanoi.
Because of the high percentage of resistance to penicillin,
erythromycin, and tetracycline among the collection of isolates,
we analyzed the corresponding resistance genes in detail. Since
the degree of genetic heterogeneity of pbp genes in both pen-
icillin-susceptible and penicillin-nonsusceptible isolates is high,
a high degree of genetic plasticity irrespective of the penicillin
resistance phenotype is suggested. This observation, which is in
contrast to previous data, which showed that penicillin-suscep-
tible pneumococci display a limited number of PBP genotypes
(36), is in line with recent findings for pneumococcal isolates
from Greece (4; Sluijter, unpublished). PBP genotype 1-1-1,
which has been predominantly observed in various pneumo-
coccal clones, including pandemic clones Spain 23F-1 and
France 9V-3 (4), was also observed in Vietnamese cluster VIII,
FIG. 2. RFEL genotypes and theoretical rates of coverage of the
seven-valent conjugate vaccine. Vaccine serotypes are depicted in grey.
Cluster codes and the number of isolates per cluster (in parentheses)
are depicted.
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which represents clone Spain 23F-1. The second largest, Viet-
nam-specific cluster, cluster VI, primarily displayed PBP geno-
type 26-3-30.
Genetic analysis of tetracycline resistance genes tet(M) and
tet(O) revealed the tet(M) gene in 91% of the Vietnamese
isolates. This is in line with observations made by Luna and
Roberts (24), who have demonstrated the presence of the
tet(M) gene in 90% of the tetracycline-resistant strains. How-
ever, in the latter study, an additional 10% of the strains
contained the tet(O) gene. Thirteen tet(M)-containing strains
were fully susceptible to tetracycline, suggesting the presence
of a nonfunctional tetracycline resistance gene. A similar ob-
servation has previously been reported by Doherty et al. (10).
The erythromycin resistance gene erm(B) was present in
82% of the pneumococcal isolates, and 10% of the erm(B)-
containing strains also harbored the mef(E) gene. This is in
contrast to recent observations made by Reinert and cowork-
ers (29), who have observed almost equal distributions of
erm(B) (43%) and mef(E) (56%) genes among erythromycin-
resistant isolates. Ten erm(B)-containing isolates and one
erm(B)- and mef(E)-containing isolate were erythromycin sus-
ceptible. To our knowledge, this is the first study to describe
the occurrence of nonfunctional erythromycin resistance genes
in pneumococci.
When our data are compared with those from a recent study
of Lee et al. (23), who have investigated pneumococcal car-
riage in healthy children in South Korea, we noticed slight
differences in the serotype distributions. In both studies the
three most common serogroups were 6, 23, and 19. However,
the rate of carriage of serotype 23F was twice as high in the
Vietnamese children with upper respiratory tract infections
(30%) as in healthy carriers in South Korea (15%), whereas
the rate of carriage of serogroup 6 was significantly higher in
the healthy children in South Korea. In both studies, serogroup
23 isolates represented international clone Taiwan 23F. As-
suming that the serotype distributions among children in Viet-
nam and South Korea are comparable, we hypothesize that
clone Taiwan 23F is more often correlated with respiratory
disease, whereas serogroup 6 is more frequently correlated
with carriage. To strengthen this hypothesis, comparative epi-
demiological studies demonstrating a significant correlation
between pneumococcal carriage and respiratory disease are
required.
In conclusion, our study demonstrated a high theoretical
rate of coverage of the seven-valent conjugate vaccine against
pneumococcal carriage strains isolated from children with
acute respiratory tract infections in Hanoi. Moreover, the ge-
notypes transmitted the most frequently were covered by the
conjugate vaccine. Finally, 78% of the pneumococcal isolates
are multidrug resistant, and 92% of these multidrug-resistant
isolates are theoretically covered by the seven-valent conjugate
vaccine. Our data suggest that the children in Vietnam will
benefit from implementation of vaccination with the pneumo-
coccal conjugate vaccine.
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